Table 1.

Additional Fibrogenic Protein and Myofiber Diameter Findings in Serum, and Flexor Digitorum Muscle and Tendons

Analyte and Tissue	FRC Untreated (n = 5–9)	FRC + hIgG (n = 5)	FRC + Saline (n = 4–7)	3‐Week HRHF Untreated (n = 8–10)	3‐week HRHF + hIgG (n = 5)	3‐Week HRHF + FG‐3019 (n = 4–7)
Serum collagen type 3 (pg/ml) (n = 5–7/group)*	75.93 ± 9.39	92.96 ± 29.38	74.32 ± 23.99	114.47 ± 18.43	106.90 ± 36.41	137.12 ± 18.71
Muscle collagen type 3, pg/μg total protein* (n = 4–9/group)	0.02 ± 0.003	0.03 ± 0.001	0.03 ± 0.005	0.08 ± 0.03	0.05 ± 0.01	0.02 ± 0.004
Muscle myofibroblasts	0.67 ± 0.67	NT	0.17 ± 0.17	1.25 ± 0.38 a	NT	0.44 ± 0.24
SMA+PDGFR+tcf4+ cells/field of 0.26 mm2
Tendon CCN2, pg/μg total protein* (n = 4–10/group)	0.09 ± 0.05	0.19 ± 0.03	0.26 ± 0.06	0.49 ± 0.17 a	0.53 ± 0.03 a	0.20 ± 0.07 b , c
Endotendon: no. of cells/mm2	0.001 ± 0.0006	0.001 ± 0.0003	0.001 ± 0.0003	0.002 ± 0.001	0.002 ± 0.001	0.001 ± 0.0003
(n = 5–6/group)
Endotendon cell shape factor; spindle‐shaped ≤0.5≥ rounded (n = 5–6/group)	0.27 ± 0.01	0.22 ± 0.05	0.18 ± 0.02	0.55 ± 0.17	0.61 ± 0.12	0.45 ± 0.05
Tendon collagen type 1, pg/μg total protein* (n = 4–8/group)	4.51 ± 0.64	5.90 ± 0.48	5.44 ± 0.79	7.81 ± 01.30 a	10.25 ± 0.99 a	10.02 ± 1.18 a
Tendon collagen type 3, pg/μg total protein* (n = 4–8/group)	0.25 ± 0.02	0.23 ± 0.03	0.19 ± 0.02	0.18 ± 0.04	0.26 ± 0.01	0.24 ± 0.04
Myofiber diameters (mcm)	37.53 ± 2.60	37.38 ± 6.27	37.73 ± 2.86	35.26 ± 3.60	37.59 ± 1.89	39.03 ± 4.21
(n = 5–6/group)

FRC, food‐restricted control; HRHF, high repetition high force; IgG, immunoglobulin G; NT, not tested.

Significant changes are bolded.

^*Enzyme‐linked immunosorbent assay.

^a p < 0.05 and ^aa p < 0.01, compared with matched FRC group.

^b p < 0.05 and ^bb p < 0.01, compared with untreated HRHF rats.

^c p < 0.05 and ^cc p < 0.01, compared with HRHF + hIgG rats.